Skip to main content
Clinical Trials/NCT01612832
NCT01612832
Unknown
Not Applicable

Peri-incisional Pregabalin for Postoperative Pain Attenuation and Analgesics Spare in Elective Neurosurgical Patients: A Randomized, Comparative, Placebo-controlled, Double Blind Study

Tel-Aviv Sourasky Medical Center0 sites100 target enrollmentJune 2012

Overview

Phase
Not Applicable
Intervention
Pregabalin
Conditions
To Assess the Beneficial Preemptive and Preventive Effects of PGL on the Immediate and Late (1- and 3 Months) Postoperative Analgesia Requirements
Sponsor
Tel-Aviv Sourasky Medical Center
Enrollment
100
Primary Endpoint
Subjectively-rated pain intensity, using a 0-10 NRS (0=no pain, 10 = unbearable pain)
Last Updated
13 years ago

Overview

Brief Summary

Background:

Proper pain relief is a major concern of patients worldwide. Preoperatively, one of the most common questions asked by patients pertains to the amount of pain they will experience after surgery how long it will last and how good will it be controlled. Pain concerns the surgical team as well, because of its correlation with clinical outcomes and patients' satisfaction rate. Studies have shown that negative clinical outcome with regard to pain control includes decreases in vital capacity and alveolar ventilation, pneumonia, tachycardia, hypertension, myocardial ischemia, transition into chronic pain, poor wound healing, and psychological sequelae .

Pain has been found to be one of the three most common medical causes of delayed/aborted discharge after ambulatory surgery, the other two being drowsiness and postoperative nausea/vomiting. Despite progress that has been made with regard to postoperative pain control, and the development of new standards for pain control, many patients continue to experience intense pain after surgery .

Recent advances in the understanding of the particularities of central sensitization indicate that it plays an important role in post surgical and post traumatic pain and therefore should be avoided

Detailed Description

Hypothesis: No studies considered the comparison of pre-emptive and post-incisional or post-surgery PGL administration. The investigators hypothesize that the administration of PGL preemptively would diminish pain sensation, and therefore the need for pain administration in neurosurgical patients, better than postoperatively. In addition, preoperative administration could reduce the level of anxiety in these patients. It should be stressed that this study will used a placebo controlled group and at availuating placebo related psychological effective treatment versus a central efficacy of Lyrica Objectives: To assess the beneficial preemptive and preventive effects of PGL on the immediate and late (1- and 3 months) postoperative analgesia requirements and pain scores in neurosurgical patients.

Registry
clinicaltrials.gov
Start Date
June 2012
End Date
June 2013
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Michal Roll PhD,MBA

Director of the research and development

Tel-Aviv Sourasky Medical Center

Eligibility Criteria

Inclusion Criteria

  • ASA (American Society of Anesthesiologists) physical status I-III
  • patients who will undergo intracranial surgery under general anesthesia only
  • Patients undergoing awake-technique procedures will also be enrolled.

Exclusion Criteria

  • allergy to opioids, midazolam, PGL, or non-steroidal anti-inflammatory drugs (NSAIDs), dipyrone
  • history of chronic pain or psychiatric disorders and the use of centrally acting antidepressant and antipsychotic drugs. Patients longtime users of sedatives, or antiepileptics
  • soldiers and pregnant women
  • Emergency cases, DBS procedures and patients unable to comprehend and sign the consent form

Arms & Interventions

Lyrica

Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).

Intervention: Pregabalin

Control

no liryca treatment

Intervention: Control

Outcomes

Primary Outcomes

Subjectively-rated pain intensity, using a 0-10 NRS (0=no pain, 10 = unbearable pain)

Time Frame: 8 h

Similar Trials